Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis C patients. However, with introduction and validation noninvasive tests (NITs) to evaluate advanced fibrosis, direct-acting antiviral agents treatment virus (HCV), role NITs have become even more complex. There now need longitudinal monitoring elucidation cutoff values prediction liver-related comp...

Liver biopsy has long been the gold standard for the grading of hepatic inflammation and the staging of hepatic fibrosis, and has been used as the reference standard method in evaluations of plasma markers of liver disease. In the modern era with the use of ultrasound guidance, biopsy is an essentially safe procedure with a 0.3% rate of serious complications, such as postprocedure pain or bleed...

Non-alcoholic fatty liver diseases (NAFLD) are the most occurring chronic liver diseases caused by hepatic manifestation of metabolic syndromes like insulin resistance in Type-2 diabetes, obesity and hyperlipidemic condition. Indian men have a high prevalence of NAFLD. Genetic factor is also an important consideration for NAFLD. The core aim of this study is to focus on non-invasive biochemical...

Liver fibrosis is part of the structural and functional alterations in most chronic liver diseases. It is one of the main prognostic factors as the amount of fibrosis is correlated with the risk of developing cirrhosis and liver-related complications in viral and nonviral chronic liver diseases [1,2]. Liver biopsy has traditionally been considered the reference method for evaluation of tissue d...

Traditionally liver biopsy has been the gold standard in evaluation of chronic liver diseases and just recently few technics of assessing liver fibrosis have replaced liver biopsy in some instances [2]. Although the etiology of most of chronic liver diseases could be diagnosed by available biochemical, serologic, immunologic and molecular examination but histologic evaluation still has a close ...

BACKGROUND Liver histology remains the gold standard for assessing non-alcoholic fatty liver disease (NAFLD). Noninvasive serological markers and radiological methods have been developed to evaluate steatosis to avoid biopsy. AIM To put cutoff value for liver enzymes that could predict non-alcoholic steatohepatitis (NASH). PATIENTS AND METHODS This study was conducted on 54 patients (with N...